Oppenheimer Maintains Perform on Enanta Pharma, Lowers Price Target to $21
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained a Perform rating on Enanta Pharma (NASDAQ: ENTA) but has reduced the price target from $25 to $21.
November 22, 2023 | 6:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Oppenheimer has maintained a Perform rating on Enanta Pharma but lowered the price target from $25 to $21, indicating a potential downside or limited upside.
The reduction in price target by a prominent analyst like Jay Olson from Oppenheimer suggests that the market expectations for Enanta Pharma's future performance have been adjusted downwards. This could lead to a negative sentiment among investors in the short term, potentially causing a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100